World Influenza Vaccine Market to Reach USD 5 Bn by 2022, Forecasts iGATE Research in Its New Report Recently Added at MarketPublishers.com
19 Apr 2017 • by Natalie Aster
LONDON – Today, influenza viruses are viewed as a key cause of mortality and morbidity worldwide. Huge population pool, considerably low vaccination coverage across emerging nations, enhancing government support for immunization and also enhancing awareness of the value of influenza vaccine in the disease prevention are likely to boost growth in the global influenza vaccines market in the years ahead.
By 2022, the global influenza vaccines market is set to amount to the value of USD 5 billion.
North America is the dominant market for influenza vaccines worldwide, the region captured a share of approximately 50% as of 2016. It is followed by Asia and Europe. Country-wise, the US holds the top position in the global market, followed by Japan.
New insightful report “Global Influenza Vaccines Market, Persons Vaccinated, Brand Analysis and Forecast to 2022” elaborated by iGATE Research gives a clear understanding of the rapidly evolving influenza vaccines market and provides access to important historical and present estimates. The study describes the current market landscape, covers the existing and emerging products, reviews the main influencing factors, identifies top challenges and opportunities and also explores the prevailing trends and performance of the leading geographical markets for influenza vaccines. The report highlights the competitive landscape and pinpoints the leading players. In addition, a future outlook through 2022 is at hand in the report.
For a full list of research reports by this publisher visit the iGATE Research catalogue at MarketPublishers.com.